首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1845907

全球鈣化胚抗原 (CEA) 市場規模（按最終用戶、應用、區域範圍和預測）

Global Carcinoembryonic Antigen (CEA) Market Size By End User (Hospitals, Diagnostic Laboratories, Clinics), By Application (Colorectal Cancer, Lung Cancer, Breast Cancer), By Geographic Scope And Forecast

出版日期: 2025年09月04日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

鈣胚抗原（CEA）市場規模及預測

預計 2024 年癌胚抗原 (CEA) 市場規模將達到 23.4 億美元，到 2031 年將達到 37.7 億美元，2024 年至 2031 年的複合年成長率為 6.10%。

鈣胚抗原 (CEA) 是一種在胚胎組織中含量豐富的醣蛋白，在成人體內含量較低。 CEA 被用作腫瘤標記，其血液水平可以提示某些腫瘤的存在，尤其是結直腸癌。健康個體的 CEA 水平通常相對較低，但在存在惡性腫瘤（如肺癌、乳癌、胰腺癌和胃腸道癌）時可能會升高。 CEA 檢測通常用於監測癌症治療後的進展和復發，而不是用於初步診斷。後續觀察升高的 CEA 水平（這可能表示疾病復發）在手術或化療後尤其有益。

隨著研究的進展，CEA 的作用預計將擴展到癌症監測之外。未來生物技術的進步可能會提高 CEA 檢測的敏感度和特異性，從而有可能實現更早的癌症檢測並將其作為治療標靶。 CEA 數據還可以利用人工智慧和機器學習整合到更廣泛的生物標記組中，從而實現更詳細、更個人化的癌症診斷。這將有助於更準確的預後、個人化治療並改善患者預後。液態切片技術的進步有望使基於 CEA 和其他標誌物的非侵入性血液診斷徹底改變癌症篩檢和監測。

全球鈣化胚抗原（CEA）市場動態

影響全球癌胚抗原 (CEA) 市場的關鍵市場動態包括：

關鍵市場促進因素

大腸直腸癌發生率不斷上升：大腸直腸癌發生率不斷上升是CEA市場的主要驅動力，CEA被廣泛用作此類癌症的腫瘤標記。根據世界衛生組織（WHO）下屬國際癌症研究機構（IARC）的數據，2020年全球將新增約193萬例大腸直腸癌病例，使其成為全球第三大常見癌症。如此高的發生率推動了CEA檢測的需求，用於早期發現和監測大腸癌。

CEA 檢測在癌症管理中的應用日益廣泛：CEA 檢測在癌症管理中的應用日益廣泛，尤其是在監測治療反應和檢測復發方面，這正在推動市場成長。《臨床腫瘤學雜誌》發表的一項研究發現，CEA 監測在結直腸癌復發出現臨床症狀之前就能檢測到 82% 的複發，這凸顯了 CEA 檢測在治療後監測中的重要性。如此高的檢測率正鼓勵更多腫瘤科醫師將 CEA 檢測納入其標準追蹤方案。

CEA 檢測的技術進步：CEA 檢測技術的創新，例如開發更靈敏、特異性的檢測方法，正在推動市場擴張。例如，根據美國美國癌症研究所的報告，使用液態切片技術（包括循環腫瘤 DNA (ctDNA) 分析）可以比傳統方法更靈敏地檢測 CEA。一項研究表明，ctDNA 分析可以檢測出 II 期結腸癌患者術後的分子殘留病灶，靈敏度高達 58%，特異性高達 98%，這有望提高 CEA 檢測在癌症管理中的效用。

主要挑戰

敏感性和特異性不足：CEA 檢測通常缺乏足夠的敏感性和特異性，尤其是在早期癌症中。 CEA 水平升高不僅限於惡性腫瘤，在吸煙、感染疾病和發炎性疾病等良性疾病中也可能升高。這會導致假陽性和假陰性，限制了效用。對於臨床醫生來說，這給解讀 CEA 水平帶來了挑戰。由於單憑該標記無法可靠地區分癌症和非癌症疾病，因此需要額外的診斷工具和程序來確認或排除惡性腫瘤。

原發性診斷效用有限：CEA 在癌症復發和進展監測的應用遠多於原發性診斷。這限制了其作為早期診斷工具的市場潛力。在癌症早期，CEA 水平可能仍處於正常範圍內，因此並非篩檢或識別惡性腫瘤早期發生的可靠指標。因此，其在癌症診斷中的應用通常有限，從而降低了一般人群對常規 CEA 檢測的需求，這直接影響了市場成長和商業性價值。

來自先進生物標記的競爭：循環腫瘤DNA (ctDNA) 等新型、更靈敏的癌症生物標記和基因檢測的興起，對CEA的相關性構成了重大挑戰。這些先進的標誌物提供了更高的準確性和更佳的早期檢測能力。隨著研發和技術創新不斷開發出更全面的癌症生物標記組合，CEA通常被視為一種過時的輔助工具。人們對先進診斷方法的日益偏好降低了對CEA檢測的依賴，威脅到其市場地位，並推動了持續改進的需求。

主要趨勢

癌症發生率上升：全球癌症患者數量的不斷增加，尤其是大腸癌和肺癌，是CEA市場的主要驅動力。由於CEA通常用於監測這些類型的癌症，因此發生率的上升直接轉化為對CEA檢測需求的增加。人口老化、吸菸等生活方式因素以及環境影響正在加劇癌症負擔。因此，CEA在癌症診斷、監測和治療後追蹤的應用越來越頻繁，這也增加了定期檢測以發現復發和追蹤治療後續觀察的需求。

早期癌症檢測意識的提升：隨著人們對早期癌症檢測重要性的認知不斷提高，越來越多的人開始接受定期篩檢和監測。癌胚抗原 (CEA) 在後續護理中發揮著至關重要的作用，尤其對於癌症復發風險較高的人。推廣早期癌症篩檢和監測的宣傳活動和醫療保健舉措，加上醫療基礎設施的進步，正在推動對 CEA 等腫瘤標記檢測的需求成長。這種日益增強的意識正在推動市場成長，因為越來越多的患者和醫生將 CEA 檢測作為綜合癌症管理策略的一部分。

診斷技術的進步：診斷技術的創新，例如檢測靈敏度的提升和自動化檢測平台的完善，正在推動CEA市場的發展。這些進步提高了CEA檢測的準確性和便利性，使其更加可靠、便利。更新、更快速、更準確的檢測方法使CEA能夠更有效地納入常規癌症監測。這些技術進步使醫療保健專業人員對CEA檢測的可靠性充滿信心，並使患者受益於更快的結果和更早的檢測，從而推動CEA檢測在臨床環境中得到更廣泛的應用。

Carcinoembryonic Antigen ((CEA)) is a glycoprotein found largely in embryonic tissues and at low levels in adults. It is employed as a tumor marker, which means that its blood levels can signal the existence of specific tumors, particularly colorectal cancer. (CEA) levels are normally relatively low in healthy persons, but they can grow in the presence of malignancies such as lung, breast, pancreatic, and gastrointestinal cancers. (CEA) testing is most typically used to monitor the course or return of cancer after therapy, rather than for initial diagnosis. It is especially beneficial in post-surgical or chemotherapy follow-ups to monitor any increase in (CEA) levels that may suggest disease recurrence.

As research improves, (CEA)'s role is predicted to grow beyond cancer monitoring. Future advances in biotechnology may improve the sensitivity and specificity of (CEA) testing, potentially enabling early cancer identification or even the use of (CEA) as a therapeutic target. (CEA) data could be integrated into broader biomarker panels via artificial intelligence and machine learning, allowing for more thorough, customized cancer diagnosis. This could result in more precise prognoses, customized treatments, and improved patient outcomes. As liquid biopsy technologies advance, non-invasive blood diagnostics based on (CEA) and other markers could transform cancer screening and monitoring

Global Carcinoembryonic Antigen (CEA) Market Dynamics

The key market dynamics that are shaping the global carcinoembryonic antigen (CEA) market include:

Key Market Drivers:

Increasing Incidence of Colorectal Cancer: The rising prevalence of colorectal cancer is a significant driver for the (CEA) market, as (CEA) is widely used as a tumor marker for this type of cancer. According to the World Health Organization's International Agency for Research on Cancer (IARC), in 2020, there were approximately 1.93 million new cases of colorectal cancer worldwide, making it the third most common cancer globally. This high incidence rate is driving the demand for (CEA) tests for early detection and monitoring of colorectal cancer.

Growing Adoption of (CEA) Tests in Cancer Management: The increasing use of (CEA) tests in cancer management, particularly for monitoring treatment response and detecting recurrence, is driving market growth. A study published in the Journal of Clinical Oncology found that (CEA) monitoring detected 82% of colorectal cancer recurrences before they were clinically apparent, highlighting its importance in post-treatment surveillance. This high detection rate is encouraging more oncologists to incorporate (CEA) testing into their standard follow-up protocols.

Technological Advancements in (CEA) Testing Methods: Innovations in (CEA) testing technologies, such as the development of more sensitive and specific assays, are driving market expansion. For instance, a report by the National Cancer Institute states that the use of liquid biopsy techniques, including circulating tumor DNA (ctDNA) analysis, can detect (CEA) with higher sensitivity than traditional methods. One study showed that ctDNA analysis could detect post-surgical molecular residual disease in stage II colon cancer patients with 58% sensitivity and 98% specificity, potentially improving the utility of (CEA) testing in cancer management.

Key Challenges:

Lack of Sensitivity and Specificity: (CEA) tests often lack sufficient sensitivity and specificity, especially in early-stage cancers. Elevated (CEA) levels are not exclusive to malignancies; benign conditions like smoking, infections, and inflammatory diseases can also cause an increase. This leads to false positives and negatives, limiting its utility in early cancer detection. For clinicians, this creates a challenge in interpreting (CEA) levels, as the marker alone cannot reliably differentiate between cancerous and non-cancerous conditions, thus requiring additional diagnostic tools and procedures to confirm or rule out malignancies.

Limited Utility in Primary Diagnosis: (CEA) is more useful for monitoring cancer recurrence or progression than for primary diagnosis. This limits its market potential as an early diagnostic tool. Since (CEA) levels may remain within normal ranges during the early stages of cancer, it is not a reliable marker for screening or identifying the initial onset of malignancy. Consequently, its application in cancer diagnosis is often restricted, reducing the demand for routine (CEA) testing in the general population, which directly impacts its market growth and commercial value.

Competition from Advanced Biomarkers: The rise of newer, more sensitive cancer biomarkers and genetic tests, such as circulating tumor DNA (ctDNA), poses a significant challenge to (CEA)'s relevance. These advanced markers provide higher precision and better early detection capabilities. As research and technological innovations continue to develop more comprehensive panels of cancer biomarkers, (CEA) is often seen as an outdated or supplementary tool. This growing preference for advanced diagnostics reduces the reliance on (CEA) testing, threatening its market position and driving the need for continuous improvement.

Key Trends:

Rising Cancer Incidence: The global increase in cancer cases, particularly colorectal and lung cancers, is a major driver for the (CEA) market. As (CEA) is commonly used to monitor these types of cancers, the rising incidence directly correlates with a higher demand for (CEA) testing. The aging population, lifestyle factors such as smoking, and environmental influences contribute to the growing cancer burden. This results in more frequent use of (CEA) as part of cancer diagnosis, monitoring, and post-treatment follow-up, thus fueling the need for regular testing to detect recurrence or track treatment efficacy.

Growing Awareness of Early Cancer Detection: As public awareness about the importance of early cancer detection rises, more individuals undergo regular screenings and monitoring. (CEA) plays a crucial role in follow-up care, especially for those at high risk of cancer recurrence. Campaigns and healthcare initiatives promoting early cancer screening and monitoring, coupled with advancements in healthcare infrastructure, lead to a higher demand for tumor marker tests like (CEA). This increased awareness drives market growth, as more patients and physicians seek out (CEA) testing as part of a comprehensive cancer management strategy.

Advancements in Diagnostic Technologies: Innovations in diagnostic technology, such as improved assay sensitivity and automated testing platforms, are boosting the (CEA) market. These advancements enhance the accuracy and ease of conducting (CEA) tests, making them more reliable and accessible. With new, faster, and more precise testing methods, (CEA) can be integrated into routine cancer monitoring more effectively. This technological progress has led to greater adoption of (CEA) testing in clinical practice, as healthcare providers become more confident in its reliability and patients benefit from faster results and earlier detection.

Global Carcinoembryonic Antigen (CEA) Market Regional Analysis

Here is a more detailed regional analysis of the global carcinoembryonic antigen (CEA) market:

North America:

North America remains a dominating participant in the Carcinoembryonic Antigen ((CEA)) testing market, because of advanced healthcare systems and rising cancer rates, notably colorectal and lung malignancies. The high prevalence of these malignancies, combined with (CEA)'s importance as a biomarker, drives demand for diagnostic testing. In 2023 alone, the United States is expected to have 153,020 new colorectal cancer cases, with lung cancer accounting for 238,340 new cancer-related fatalities. The increase in survival rates for these tumors, owing to early detection approaches such as (CEA) testing, emphasizes its importance in the region's healthcare scene.

The global (CEA) market is also expected to rise rapidly, owing to advances in biomarker testing technologies and increased acceptance of customized medicine. According to studies, combining (CEA) with additional biomarkers greatly boosts detection rates, hence increasing early diagnosis efforts. With the worldwide cancer biomarkers market predicted to increase at a 12.2% CAGR until 2028, continuous research and technological innovations will continue to fuel market growth. North America's emphasis on precision medicine and early cancer detection, combined with significant research initiatives, strengthens its position in the worldwide (CEA) market.

Asia-Pacific:

The Asia-Pacific region is witnessing rapid growth in the Carcinoembryonic Antigen ((CEA)) market, driven primarily by a rising cancer incidence, advancements in healthcare infrastructure, and increasing awareness of early cancer detection. As cancer rates climb, particularly with projections showing a 30.7% rise in new cancer cases from 8.8 million in 2018 to 11.5 million by 2030 (WHO), the demand for diagnostic tests like (CEA) is expected to surge. These factors contribute to the rising accessibility and availability of (CEA) testing across the region.

Another significant driver is the increase in disposable incomes and the expansion of the middle class, allowing more individuals to afford advanced diagnostic procedures like (CEA) testing. The Asian Development Bank forecasts the middle-class population in Asia will grow to 3.5 billion by 2030, which will significantly boost demand for healthcare services. Additionally, the growing prevalence of colorectal cancer, one of the primary cancers detected by (CEA) tests, is further fueling market growth. GLOBOCAN 2020 estimates a 60% rise in colorectal cancer cases by 2040 in Asia, reinforcing the need for more widespread diagnostic testing. Government initiatives, such as China's "Healthy China 2030" plan to improve early detection and cancer survival rates, further support the upward trajectory of the (CEA) market in the region.

Carcinoembryonic Antigen (CEA) Market: Segmentation Analysis

The Global Carcinoembryonic Antigen (CEA) Market is Segmented on the basis of End User, Application, And Geography.

Carcinoembryonic Antigen (CEA) Market, By End User

Hospitals

Diagnostic Laboratories

Clinics

Based on End User, the market is fragmented into Hospitals, Diagnostic Laboratories, and Clinics. Hospitals lead the Carcinoembryonic Antigen ((CEA)) market as they have access to advanced diagnostic tools, competent healthcare workers, and a large volume of cancer-related treatments. Hospitals are typically the primary site of care for cancer patients, and (CEA) tests are commonly used for diagnosis and monitoring. The diagnostic laboratories industry is rapidly growing, driven by rising demand for specialized, high-precision testing and the trend of outsourcing diagnostic services. These labs have enhanced capabilities and rapid turnaround times, which strengthens their role in assisting hospitals and clinics with cancer diagnosis and management.

Carcinoembryonic Antigen (CEA) Market, By Application

Colorectal Cancer

Lung Cancer

Breast Cancer

Based on Application, the market is divided into Colorectal Cancer, Lung Cancer, and Breast Cancer. The colorectal cancer segment dominates the Carcinoembryonic Antigen ((CEA)) market since (CEA) is well established as a biomarker for monitoring and detecting recurrence in colorectal cancer patients. (CEA) testing is widely used to determine both prognosis and therapy efficacy, making it an important tool in cancer management. The lung cancer category is also fast expanding, spurred by advances in early detection and the rising global prevalence of lung cancer. With the emergence of non-invasive testing technologies, (CEA) is becoming a key marker for some forms of lung cancer, which is driving market growth.

Carcinoembryonic Antigen (CEA) Market, By Geography

Europe

North America

Asia Pacific

Rest of the world

On the basis of geographical analysis, the Global Carcinoembryonic Antigen (CEA) Market is classified into Europe, North America, Asia Pacific, and rest of the world. North America leads considering to its well-established healthcare infrastructure, strong awareness of cancer screening, and the presence of major industry participants such as Roche Diagnostics and Abbott Laboratories. The region benefits from substantial investments in cancer research and innovative diagnostic technologies. The Asia-Pacific area is experiencing the highest growth, owing to rising cancer incidence, a rapidly expanding middle class, and increased government initiatives aimed at early cancer identification. Countries such as China and India are spending considerably on healthcare infrastructure and increasing access to modern diagnostics, positioning Asia Pacific as a potential growth market for (CEA) testing.

Key Players

The "Global Carcinoembryonic Antigen (CEA) Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Roche Diagnostics, Abbott Laboratories, Siemens Healthiness', Thermo Fisher Scientific, Quest Diagnostics, Beckman Coulter, and GenWay Biotech.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Carcinoembryonic Antigen (CEA) Market Recent developments
In December 2023, Sanofi discontinued its global scientific research initiative for tusamitamab ravtansine. This decision is based on the results of a predefined intervening time analysis of the Phase 3 CARMEN-LC03 study, which compares tusamitamab ravtansine as a monotherapy to docetaxel in previously treated patients with metastatic non-squamous non-small cellular lung cancer (NSCLC).
In May 2022, the University of Texas MD Anderson Cancer Center and Virogin Biotech announced a strategic collaboration to accelerate the development of investigational treatments, including oncolytic viruses and immunotherapies, for patients with advanced cancers.

1 INTRODUCTION OF GLOBAL CARCINOEMBRYONIC ANTIGEN (CEA) MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL CARCINOEMBRYONIC ANTIGEN (CEA) MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL CARCINOEMBRYONIC ANTIGEN (CEA) MARKET, BY APPLICATION

5.1 Overview
5.2 Gastrointestinal Cancer
5.3 Breast Cancer
5.4 Lung Cancer
5.5 Others

6 GLOBAL CARCINOEMBRYONIC ANTIGEN (CEA) MARKET, BY GENDER

6.1 Overview
6.2 Male
6.3 Female

7 GLOBAL CARCINOEMBRYONIC ANTIGEN (CEA) MARKET, BY END-USERS

7.1 Overview
7.2 Hospitals
7.3 Diagnostic Centres
7.4 Research and academic institutes
7.5 Family
7.6 Others

8 GLOBAL CARCINOEMBRYONIC ANTIGEN (CEA) MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East and Africa

9 GLOBAL CARCINOEMBRYONIC ANTIGEN (CEA) MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Quest Diagnostics
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Abbott Diagnostics
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Roche Diagnostics
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 GenWay Biotech Inc.
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Correlogic Systems, Inc.
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Creative Diagnostics
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Omega Diagnostics Group PLC
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 RayBiotech Inc.
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Boster Biological Technology
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments